The DilemmaPerhaps the company’s equity price is indicative of a dilemma that long term share holders have experienced all too often. The company has indicated that the current phase 2 trial could last until 2024-2025. Despite its insistence, the company’s financial coffers do not necessarily equate to those stated target dates.
Thus...the dilemma...where will the money be generated to accomplish the company’s goals? It seems the market is telling us another PP is probably more realistic than a JV or even a buyout.
And so it is...I never thought I’d be thinking this (or even writing it) when I first invested in 2014.
John